Alvogen today announced the launch of the first generic equivalent of Revlimid™ (lenalidomide) in several CEE markets including Romania, Croatia, Bulgaria and the Baltic states. The product will be marketed as 2.5, 5, 7.5, 10, 15, 20, 25mg hard capsules and is a fully generic and bioequivalent product to Revlimid™. Following the launch into multiple CEE countries, Alvogen’s Lenalidomide will also be launched in selected Asian countries in 2019.
Alvogen’s Lenalidomide has been developed fully in-house at Alvogen‘s subsidiary, Lotus Pharmaceuticals and is part of a comprehensive oncology pipeline.
Hacho Hathcikian, Executive Vice President at Alvogen in the CEE regions, said: “The Lenalidomide launch is a major landmark for Alvogen in the CEE region as we are the first generic pharmaceutical company to launch the generic of Revlimid™ in our major markets. Patients now finally have access to an affordable and high-quality generic alternative of this leading oncology drug. Adding Lenalidomide to our portfolio also enhances our commitment to be one of the key oncology players in the CEE region.”
Revlimid™ is indicated for several hematological malignancies including multiple myeloma and is the biggest-selling oncology drug with approximately $9.8 billion sales globally.
Revlimid™ is a trademark of Celgene Corporation